drugset / Trial / NCT00233610

Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer

NCT00233610

Phase 3 Completed 180 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelPrevention

Summary

The aim of the study is to investigate the efficacy of different dosing and scheduling of Nolvadex in preventing gynecomastia/mastalgia induced by Casodex 150 mg monotherapy in patients with prostate cancer.

Timeline

Start
2003-12
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamoxifen Small molecule
Background Bicalutamide Other / unclassified 150 mg

Indications